Reported are three children with MS who responded dramatically to interferon-β (IFNβ) therapy. While on immunomodulatory therapy, they developed chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) that responded to IV immunoglobulin (IVIG) administration. These cases emphasize two interesting observations: 1) IFNβ treatment did not prevent development of CIDP; 2) CIDP in the context of MS responded to IVIG, even though IVIG had no therapeutic effect on the central demyelinating disease.
|Original language||English (US)|
|Number of pages||3|
|State||Published - May 27 2003|
ASJC Scopus subject areas
- Clinical Neurology